Statins in Ischemic Stroke: Just Low-Density Lipoprotein Lowering or More?

Journal of Stroke and Cerebrovascular Diseases

Volumn 18, Issue 2, 2009, Pages 124-127

  Stead, Latha G ^a   Vaidyanathan, Lekshmi ^a   Kumar, Gautam ^a   Bellolio, M Fernanda ^a   Brown Jr , Robert D ^a   Suravaram, Smitha ^a   Enduri, Sailaja ^a   Gilmore, Rachel M ^a   Decker, Wyatt W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain; cholesterol; ischemia; ischemic stroke; low density lipoprotein; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FUNCTIONAL STATUS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BRAIN; BRAIN CHEMISTRY; BRAIN ISCHEMIA; CHOLESTEROL; COHORT STUDIES; CYTOPROTECTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 60949086201     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2008.09.016     Document Type: Article

References (18)

1. Rosamond W., Flegal K., Furie K., et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2008 update: A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 117 (2008) e25-e146
2. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
3. Williams L.S., Yilmaz E.Y., and Lopez-Yunez A.M. Retrospective assessment of initial stroke severity with the NIH stroke scale. Stroke 31 (2000) 858-862
4. Kasner S.E., Chalela J.A., Luciano J.M., et al. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke 30 (1999) 1534-1537
5. Shinohara Y., Minematsu K., Amano T., et al. Modified Rankin scale with expanded guidance scheme and interview questionnaire: Interrater agreement and reproducibility of assessment. Cerebrovasc Dis 21 (2006) 271-278
6. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial; TOAST, trial of org 10172 in acute stroke treatment. Stroke 24 (1993) 35-41
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002) 3143-3421
8. Elkind M.S., Flint A.C., Sciacca R.R., et al. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 65 (2005) 253-258
9. Martí-Fàbregas J., Gomis M., Arboix A., et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35 (2004) 1121-1123
10. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 326 (2003) 1423
11. Amarenco P., Bogousslavsky J., Callahan A.S., et al. SPARCL Investigators. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 16 (2003) 389-395
12. Endres M., Laufs U., Huang Z., et al. Stroke prevention by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95 (1998) 8880-8885
13. Amin-Hanjani S., Stagliano N.E., Yamada M., et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 (2001) 980-986
14. Chen J., Zhang Z.G., Li Y., et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53 (2003) 743-751
15. Sacco R.L., Adams R., Albers G., et al. American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke. Stroke 37 (2006) 577-617
16. Blanco M., Nombela F., Castellanos M., et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 69 (2007) 904-910
17. Colivicchi F., Bassi A., Santini M., et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38 (2007) 2652-2657
18. Montaner J., Chacón P., Krupinski J., et al. Simvastatin in the acute phase of ischemic stroke: A safety and efficacy pilot trial. Eur J Neurol 15 (2008) 82-90